



PROFILING MIGRAINE IN A LOW-RESOURCE TERTIARY HOSPITAL
ONE-YEAR OVERVIEW OF PREVENTIVE STRATEGIES

Devi Ariani Sudibyo¹, Isti Suharjanti²

¹Neurology Staff, Faculty of Medicine, Universitas Airlangga / Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
²Neurology Staff, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia


Objective

Migraine represents a substantial cause of global disability, especially among working-age adults, exerting a greater burden in low- and middle-income countries where access to effective treatment remains limited. This study aims to evaluate the clinical profile of migraine patients at Dr. Soetomo General Academic Hospital in 2024, focusing on demographic patterns and the distribution of preventive treatment options to improve patient care and treatment outcomes.

Methods


This study is a retrospective analysis of migraine cases treated at Dr. Soetomo General Academic Hospital in Surabaya from January 1, 2024, to December 31, 2024. Data were collected from patients’ electronic medical records in the neurology outpatient clinic. Demographic characteristics, such as age, gender, and the presence of migraine with or without aura, were extracted. Additionally, information regarding pharmacological treatments, including preventive medications, was provided. The severity of migraine was assessed using the Numeric Pain Rating Scale (NPRS).

Results



BEFORE TREATMENT

AFTER TREATMENT



Conclusion

This study highlights that migraines predominantly affect female patients, particularly in the 18-45 age group. While various pharmacological preventive treatments were utilized, valproic acid and topiramate emerged as the most prescribed medications in low- and middle-income countries.

[DISCLOSURE OF INTEREST : NONE

References:
1.Kim, B.-S., Chung, P.-W., Chung, J. M., Park, K.-Y., Moon, H.-S., Park, H.-K., Bae, D.-W., Seo, J.-G., Sohn, J.-H., Song, T.-J., Lee, S.-H., Oh, K., Lee, M. J., Cha, M.-J., Choi, Y.-J., & Choi, M. (2025). Evidence-Based Recommendations on Pharmacologic Treatment for Migraine Prevention: A Clinical Practice Guideline from the Korean Headache Society. Headache and Pain Research, 26(1), 5-20. <https://doi.org/10.62087/hpr.2024.0019>
2.Olesen, J. (2018). Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211. <https://doi.org/10.1177/0333102417738202>
3.Ornello, R., Caponnetto, V., Ahmed, F., Al-Khazali, H. M., Ambrosini, A., Ashina, S., Baraldi, C., Bellotti, A., Brighina, F., Calabresi, P., Casillo, F., Cevoli, S., Cheng, S., Chiang, C.-C., Chiarugi, A., Christensen, R. H., Chu, M. K., Coppola, G., Corbelli, I., ... Sacco, S. (2025). Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia, 45(4), 1-326. <https://doi.org/10.1177/03331024241305381>
4.Puledra, F., Sacco, S., Diener, H.-C., Ashina, M., Al-Khazali, H. M., Ashina, S., Burstein, R., Liebler, E., Cipriani, A., Chu, M. K., Cocores, A., Dodd-Glover, F., Ekizoglu, E., Garcia-Azorin, D., Göbel, C. H., Goicochea, M. T., Hassan, A., Hirata, K., Hoffmann, J., ... Tassorelli, C. (2024). International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia, 44(9). <https://doi.org/10.1177/03331024241269735>